Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with or without apatinib versus platinum-doublet chemotherapy as first-line treatment for PD-L1-positive recurrent or advanced NSCLC
CTR20200638Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Sep 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib, carboplatin, pemetrexed, paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Sep 2020; status: active.
02
Drugs
camrelizumabRivoceranibcarboplatinpemetrexedpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200638.